|
Characteristics
|
ASYM (n = 48)
|
CHB (n = 42)
|
LC (n = 49)
|
HCC (n = 102)
|
HCC with LC (n = 25)
|
|---|
|
Age (years)
|
36 [18–57]
|
39 [20–69]
|
57 [27–79]
|
54.5 [26–81]
|
60 [40–75]
|
|
Gender (M/F)
|
35/13
|
33/9
|
41/8
|
102/0
|
25/0
|
|
WBC* 109/L
|
6.7 [4.8–11]
|
5.99 [4.8–11.8]
|
5.6 [3.2–18]
|
6 [2.7–17]
|
5.6 [3–8.4]
|
|
RBC* 1012/L
|
5 [3.8–47]
|
4.8 [3.8–11.6]
|
4.2 [2.5–5.7]
|
4.5 [2.43–6]
|
4 [3–5.2]
|
|
PLT* 109/L
|
227 [117–376]
|
217 [117–332]
|
98 [3.7–320]
|
166 [40–382]
|
142 [35–226]
|
|
ALT* (IU/L)
|
23 [8–74]
|
47 [13–750]
|
57 [13–395]
|
42 [12–805]
|
46 [11–290]
|
|
AST* (IU/L)
|
25 [12–35]
|
38 [19–599]
|
84 [15–329]
|
54.5 [17–670]
|
116 [25–655]
|
|
Total bilirubin* (mg/dl)
|
13 [6.7–32]
|
16 [8–32]
|
29 [9–571]
|
18 [8–184]
|
27 [9.6–185]
|
|
Direct bilirubin* (mg/dl)
|
3.5 [1–8]
|
5.7 [1.4–26]
|
10 [0.4–291]
|
6 [1–80]
|
12.5 [2–59]
|
|
Albumin* (g/L)
|
42 [38–48]
|
43 [12–48]
|
30 [3.3–47]
|
38 [4–47]
|
32 [22–42]
|
|
Prothrombin* (% of standard)
|
92 [78–127]
|
94 [72–127]
|
65 [23.4–92]
|
78 [19.6–128]
|
69 [36–124]
|
|
HBV viral load* (copies/ml)
|
6.65×104
|
5.53×105
|
8.85×105
|
5.94×105
|
4.05×105
|
|
[290–6.26×109]
|
[100–9.9×108]
|
[203–4.71×108]
|
[190–2.28×109]
|
[2040–3.04×109]
|
|
Alpha–feto protein (AFP)* (mg/L)
|
NA
|
<5
|
6.8 [1.26–300]
|
79 [1.38–350]
|
300 [2.56–300]
|
|
Treatments (treated/not-treated)
| | | |
61/41
|
15/10
|
|
TOCE
|
NA
|
NA
|
NA
|
48/55
|
11/14
|
|
RFA
|
NA
|
NA
|
NA
|
18/85
|
8/17
|
|
Alcohol injection
|
NA
|
NA
|
NA
|
26/77
|
10/15
|
|
Surgery
|
NA
|
NA
|
NA
|
6/97
|
0/25
|
- ASYM, asymptomatic; CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; WBC, white blood cells; RBC, red blood cells; PLT, platelets; AST and ALT, aspartate and alanine amino transferase; IU, international units; TOCE, transcatheter oily chemoembolization; RFA, radiofrequency ablation; NA, not applicable. Values given are medians and range; (*) P < 0.05 for comparison with all other groups.
